Glenmark Pharmaceuticals receives three observations from USFDA for Indore plant

21 Apr 2016 Evaluate

Glenmark Pharmaceuticals has received three observations from the US Food and Drug Administration (USFDA) for its Pithampur, Indore plant, which was inspected by USFDA in February 2016. However, the company has responded to the observations in March 2016.  Subsequently, the company received two product approvals from this plant and the company has no outstanding items with the USFDA regarding this plant.

Glenmark is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), with seven molecules in various stages of clinical development & pre-clinical development. The company has a significant presence in branded generics markets across emerging economies including India.

Glenmark Pharma Share Price

2035.90 6.30 (0.31%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×